CDB INT'L INV (01062) announces interim results, with a net loss of approximately HK$11.68 million, a 90.6% decrease year-on-year.
China Overseas International Investment (01062) announces its mid-term performance for 2025, with a net loss of approximately 1168.2 million Hong Kong dollars, a year-on-year...
CDB INT'L INV (01062) announces its mid-term performance in 2025, with a net loss of approximately HK$11.682 million, a year-on-year narrowing of 90.6%; loss per share is 0.4 HK cents.
The announcement stated that the loss was mainly due to the fair value gains and losses on financial assets measured at fair value through profit or loss, with a net loss of approximately HK$4.69 million (first half of 2024: net loss of approximately HK$124.41 million), and general and administrative expenses incurred during the period of approximately HK$12.26 million (first half of 2024: approximately HK$4.06 million). During the period, the Group's interest income was approximately HK$5.37 million (first half of 2024: approximately HK$0.96 million). The net loss of fair value gains and losses on financial assets measured at fair value through profit or loss for this period was approximately HK$4.69 million (first half of 2024: net loss of approximately HK$124.41 million).
Related Articles

HATCHER GROUP (08365) signs partnership agreement with EF HongKong and EF Commodities and may make equity investments in Esperanza.

GAPACK (00468) will distribute a final dividend of HK$0.22 per share on September 30th.

KONTA CHINA (01312): Tongfang Pharmaceuticals and Beijing Qingkong signed a construction contract in Beijing with a capital investment of approximately 33.67 million yuan.
HATCHER GROUP (08365) signs partnership agreement with EF HongKong and EF Commodities and may make equity investments in Esperanza.

GAPACK (00468) will distribute a final dividend of HK$0.22 per share on September 30th.

KONTA CHINA (01312): Tongfang Pharmaceuticals and Beijing Qingkong signed a construction contract in Beijing with a capital investment of approximately 33.67 million yuan.

RECOMMEND

Former Innovative Pharma Star Faces Growing Pains—Why Zai Lab’s Stock Tumbled Despite Strong Results
18/08/2025

World Humanoid Robot Games In-Depth: Competition Drives Technological Innovation and Accelerates Industry Progress
18/08/2025

Guangdong Cross-Border E-Commerce: Tariff Pressures Spur Overseas Warehouse Boom as Sellers Target Russia and Latin America
18/08/2025